Catalyst Funds Management Pty Ltd Buys Shares of 35,200 Moderna, Inc. (NASDAQ:MRNA)

Catalyst Funds Management Pty Ltd bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 35,200 shares of the company’s stock, valued at approximately $1,464,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State Street Corp increased its stake in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after purchasing an additional 178,939 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MRNA shares. JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a research note on Friday, February 14th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Citigroup initiated coverage on shares of Moderna in a research report on Thursday. They set a “neutral” rating and a $40.00 target price for the company. Morgan Stanley dropped their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Finally, HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Monday, November 18th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $59.60.

Moderna Trading Up 0.9 %

Moderna stock opened at $34.62 on Friday. The firm has a 50-day moving average price of $35.94 and a 200-day moving average price of $47.59. The firm has a market capitalization of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.